Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a ...

A new patient advocacy organization, the ApoE4 Alzheimer’s Alliance, has launched in the U.S., with a goal of helping advance both supportive policies and the development of treatments for people with ...

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. “The approval of once every four-week ...

Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy AXS-05 as a treatment for agitation related to Alzheimer’s disease.

Zunveyl (benzgalantamine) is an approved oral therapy used to slow the progression of dementia in people with mild to moderate Alzheimer’s.

Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s ...

Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic Alzheimer’s.

Buntanetap, a small molecule from Annovis Bio, improved cognitive function in people with mild Alzheimer’s with certain biomarkers.

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Phospho-Tau 217 (pTau217), a blood-based biomarker test that can help distinguish Alzheimer’s disease ...

Many states use the Silver Alert program to track missing older adults, columnist Ray Burow writes. Read more on dementia and wandering.

These are the top-line findings of an ongoing Phase 2 clinical trial (NCT04693520), whose two-year data also showed that Alzheon ’s experimental therapy preserved the hippocampus, a brain structure ...

Anavex is preparing meetings with regulatory authorities in the U.S., Europe, and Asia-Pacific to discuss Anavex 2-73’s potential approval.